AiM  Vol.8 No.12 , December 2018
Lessons from Vibrio Pathogen and the Comparative Study of Vaccines Developed
Abstract: Cholera continues to be one of the most common causes of morbidity and mortality among children and adults in developing countries. Vaccine against cholera is an approach in the control of this epidemic and pandemic disease. From the development of very early oral cholera vaccine, advances in vaccine development documented due to a good illustration of the epidemiology, outbreak strategy, and pathophysiology of the disease causing pathogen. The newer-generation oral cholera vaccines are safe and guarantee a high level of protection during outbreak settings for several years. Yet infants and young children in developing countries are hyporesponsive to vaccines and show poor protection against cholera. In this review, we survey and analyse our current knowledge on the etiology of cholera, its clinical manifestation, global epidemiology and elaborate the vaccine candidates, which are effective against the pathogen and the corresponding immune responses to the available vaccines. These reviews comprehensively cover the salient features of recent discoveries related to Vibrio cholerae virulence, past and present vaccine candidates and their advantages and disadvantages with their development strategies. We believe that the advances that have been included in this review will give a comprehensive insight to the prevention and control of cholera outbreaks and development of effective cholera vaccines.
Cite this paper: Rahman, T. , Seraj, M. , Buroni, S. (2018) Lessons from Vibrio Pathogen and the Comparative Study of Vaccines Developed. Advances in Microbiology, 8, 950-964. doi: 10.4236/aim.2018.812064.

[1]   Lipp, E.K., Huq, A. and Colwell, R.R. (2002) Effects of Global Climate on Infectious Disease: The Cholera Model. Clinical Microbiology Reviews, 15, 757-770.

[2]   Finkelstein, R.A. (1996) Vibrio cholerae O1 and O139, and Other Pathogenic Vibrios. In: Baron, S., Ed., Medical Microbiology, 4th Edition, Chapter 24 (Cholera), Galveston, TX.

[3]   Nelson, E.J., et al. (2009) Cholera Transmission: The Host, Pathogen and Bacteriophage Dynamic. Nature Reviews Microbiology, 7, 693-702.

[4]   Ali, M., et al. (2015) Updated Global Burden of Cholera in Endemic Countries. PLoS Neglected Tropical Diseases, 9, e0003832.

[5]   Brandt, K.G., Castro Antunes, M.M. and Silva, G.A. (2015) Acute Diarrhea: Evidence-Based Management. Jornal de Pediatria, 91, S36-S43.

[6]   Jutla, A., et al. (2013) Environmental Factors Influencing Epidemic Cholera. The American Journal of Tropical Medicine and Hygiene, 89, 597-607.

[7]   Lanata, C.F., et al. (2013) Global Causes of Diarrheal Disease Mortality in Children <5 Years of Age: A Systematic Review. PloS ONE, 8, e72788.

[8]   Guthmann, J.P. (1995) Epidemic Cholera in Latin America: Spread and Routes of Transmission. The Journal of Tropical Medicine and Hygiene, 98, 419-427.

[9]   Almagro-Moreno, S., Pruss, K. and Taylor, R.K. (2015) Intestinal Colonization Dynamics of Vibrio cholerae. PLoS Pathogens, 11, e1004787.

[10]   Colwell, R.R. (1996) Global Climate and Infectious Disease: The Cholera Paradigm. Science, 274, 2025-2031.

[11]   Millet, Y.A., et al. (2014) Insights into Vibrio cholerae Intestinal Colonization from Monitoring Fluorescently Labeled Bacteria. PLoS Pathogens, 10, e1004405.

[12]   Chatterjee, S.N. and Chaudhuri, K. (2003) Lipopolysaccharides of Vibrio cholerae. I. Physical and Chemical Characterization. Biochimica et Biophysica Acta, 1639, 65-79.

[13]   Villeneuve, S., et al. (1999) Immunochemical Characterization of an Ogawa-Inaba Common Antigenic Determinant of Vibrio cholerae O1. Microbiology, 145, 2477-2484.

[14]   Alam, M., et al. (2006) Seasonal Cholera caused by Vibrio cholerae Serogroups O1 and O139 in the Coastal Aquatic Environment of Bangladesh. Applied and Environmental Microbiology, 72, 4096-4104.

[15]   Son, M.S., et al. (2011) Characterization of Vibrio cholerae O1 El Tor Biotype Variant Clinical Isolates from Bangladesh and Haiti, Including a Molecular Genetic Analysis of Virulence Genes. Journal of Clinical Microbiology, 49, 3739-3749.

[16]   Chen, C.H., Shimada, T., Elhadi, N., Radu, S. and Nishibuchi, M. (2004) Phenotypic and Genotypic Characteristics and Epidemiological Significance of ctx+ Strains of Vibrio cholerae Isolated from Seafood in Malaysia. Applied and Environmental Microbiology, 70, 1964-1972.

[17]   Meeks, M.D., et al. (2004) Synthetic Fragments of Vibrio cholerae O1 Inaba O-Specific Polysaccharide Bound to a Protein Carrier Are Immunogenic in Mice but Do Not Induce Protective Antibodies. Infection and Immunity, 72, 4090-4101.

[18]   Hu, D., et al. (2016) Origins of the Current Seventh Cholera Pandemic. Proceedings of the National Academy of Sciences of the United States of America, 113, E7730-E7739.

[19]   Nair, G.B., Faruque, S.M., Bhuiyan, N.A., Kamruzzaman, M., Siddique, A.K. and Sack, D.A. (2002) New Variants of Vibrio cholerae O1 Biotype El Tor with Attributes of the Classical Biotype from Hospitalized Patients with Acute Diarrhea in Bangladesh. Journal of Clinical Microbiology, 40, 3296-3299.

[20]   Sinha, S., et al. (2002) Escalating Association of Vibrio cholerae O139 with Cholera Outbreaks in India. Journal of Clinical Microbiology, 40, 2635-2637.

[21]   Faruque, S.M., et al. (2003) Emergence and Evolution of Vibrio cholerae O139. Proceedings of the National Academy of Sciences of the United States of America, 100, 1304-1309.

[22]   Almagro-Moreno, S. and Taylor, R.K. (2013) Cholera: Environmental Reservoirs and Impact on Disease Transmission. Microbiology Spectrum, 1.

[23]   Weill, F.X., et al. (2017) Genomic History of the Seventh Pandemic of Cholera in Africa. Science, 358, 785-789.

[24]   Poirier, M.J., Izurieta, R., Malavade, S.S. and McDonald, M.D. (2012) Re-Emergence of Cholera in the Americas: Risks, Susceptibility, and Ecology. Journal of Global Infectious Diseases, 4, 162-171.

[25]   Siddique, A.K., Zaman, K., Akram, K., Mutsuddy, P., Eusof, A. and Sack, R.B. (1994) Emergence of a New Epidemic Strain of Vibrio cholerae in Bangladesh. An Epidemiological Study. Tropical and Geographical Medicine, 46, 147-150.

[26]   Dick, M.H., Guillerm, M., Moussy, F. and Chaignat, C.-L. (2012) Review of Two Decades of Cholera Diagnostics—How Far Have We Really Come? PLoS Neglected Tropical Diseases, 6, e1845.

[27]   Keen, M.F. and Bujalski, L. (1992) The Diagnosis and Treatment of Cholera. The Nurse Practitioner, 17, 53-56.

[28]   Chowdhury, F., Khan, A.I., Faruque, A.S.G. and Ryan, E.T. (2010) Severe, Acute Watery Diarrhea in an Adult. PLoS Neglected Tropical Diseases, 4, e898.

[29]   Alexakis, L.C. (2017) Cholera—Rice Water Stools. The Pan African Medical Journal, 26, 147.

[30]   Tobin-D’Angelo, M., et al. (2008) Severe Diarrhea Caused by Cholera Toxin-Producing Vibrio cholerae Serogroup O75 Infections Acquired in the Southeastern United States. Clinical Infectious Diseases, 47, 1035-1040.

[31]   Holmgren, J. (1981) Actions of Cholera Toxin and the Prevention and Treatment of Cholera. Nature, 292, 413-417.

[32]   Ghose, A.C. (2011) Lessons from Cholera & Vibrio cholerae. The Indian Journal of Medical Research, 133, 164-170.

[33]   Bharati, K. and Ganguly, N.K. (2011) Cholera Toxin: A Paradigm of a Multifunctional Protein. The Indian Journal of Medical Research, 133, 179-187.

[34]   Lahiani, A., Yavin, E. and Lazarovici, P. (2017) The Molecular Basis of Toxins’ Interactions with Intracellular Signaling via Discrete Portals. Toxins, 9.

[35]   Taylor, M., Curtis, D. and Teter, K. (2015) A Conformational Shift in the Dissociated Cholera Toxin A1 Subunit Prevents Reassembly of the Cholera Holotoxin. Toxins, 7, 2674-2684.

[36]   Guichard, A., et al. (2013) Cholera Toxin Disrupts Barrier Function by Inhibiting Exocyst-Mediated Trafficking of Host Proteins to Intestinal Cell Junctions. Cell Host & Microbe, 14, 294-305.

[37]   Cuatrecasas, P. (1973) Gangliosides and Membrane Receptors for Cholera Toxin. Biochemistry, 12, 3558-3566.

[38]   Stanfield, C.L. (2017) Principles of Human Physiology. Pearson Global Edition.

[39]   Holmgren, J. and Svennerholm, A.M. (1977) Mechanisms of Disease and Immunity in Cholera: A Review. The Journal of Infectious Diseases, 136, S105-S112.

[40]   Levine, M.M., et al. (1979) Immunity of Cholera in Man: Relative Role of Antibacterial versus Antitoxic Immunity. Transactions of the Royal Society of Tropical Medicine and Hygiene, 73, 3-9.

[41]   Stoll, B.J., Glass, R.I., Huq, M.I., Khan, M.U., Banu, H. and Holt, J. (1982) Epidemiologic and Clinical Features of Patients Infected with Shigella Who Attended a Diarrheal Disease Hospital in Bangladesh. The Journal of Infectious Diseases, 146, 177-183.

[42]   Glass, R.I., et al. (1982) Endemic Cholera in Rural Bangladesh, 1966-1980. American Journal of Epidemiology, 116, 959-970.

[43]   Patel, S.M., et al. (2012) Memory B Cell Responses to Vibrio cholerae O1 Lipopolysaccharide Are Associated with Protection against Infection from Household Contacts of Patients with Cholera in Bangladesh. Clinical and Vaccine Immunology, 19, 842-848.

[44]   Jayasekera, C.R., et al. (2008) Cholera Toxin-Specific Memory B Cell Responses Are Induced in Patients with Dehydrating Diarrhea Caused by Vibrio cholerae O1. The Journal of Infectious Diseases, 198, 1055-1061.

[45]   Leung, D.T., Chowdhury, F., Calderwood, S.B., Qadri, F. and Ryan, E.T. (2012) Immune Responses to Cholera in Children. Expert Review of Anti-Infective Therapy, 10, 435-444.

[46]   Bishop, A.L., Schild, S., Patimalla, B., Klein, B. and Camilli, A. (2010) Mucosal Immunization with Vibrio cholerae Outer Membrane Vesicles Provides Maternal Protection Mediated by Antilipopolysaccharide Antibodies That Inhibit Bacterial Motility. Infection and Immunity, 78, 4402-4420.

[47]   Wu, J.Y., Taylor, R.K. and Wade, W.F. (2001) Anti-Class II Monoclonal Antibody-Targeted Vibrio cholerae TcpA Pilin: Modulation of Serologic Response, Epitope Specificity, and Isotype. Infection and Immunity, 69, 7679-7686.

[48]   Baranova, D.E., Levinson, K.J. and Mantis, N.J. (2018) Vibrio cholerae O1 Secretes an Extracellular Matrix in Response to Antibody-Mediated Agglutination. PLoS ONE, 13, e0190026.

[49]   Falero, G., et al. (2003) Production and Characterization of Monoclonal Antibodies to E1 Tor Toxin Co-Regulated Pilus of Vibrio cholerae. Hybridoma and Hybridomics, 22, 315-320.

[50]   Tacket, C.O., et al. (1998) Investigation of the Roles of Toxin-Coregulated Pili and Mannose-Sensitive Hemagglutinin Pili in the Pathogenesis of Vibrio cholerae O139 Infection. Infection and Immunity, 66, 692-695.

[51]   Gupta, R.K., Taylor, D.N., Bryla, D.A., Robbins, J.B. and Szu, S.C. (1998) Phase 1 Evaluation of Vibrio cholerae O1, Serotype Inaba, Polysaccharide-Cholera Toxin Conjugates in Adult Volunteers. Infection and Immunity, 66, 3095-3099.

[52]   Haney, D.J., Lock, M.D., Simon, J.K., Harris, J. and Gurwith, M. (2017) Antibody-Based Correlates of Protection against Cholera Analysis of a Challenge Study in a Cholera-Naive Population. Clinical and Vaccine Immunology, 24, e00098-17.

[53]   Mantis, N.J., Rol, N. and Corthesy, B. (2011) Secretory IgA’s Complex Roles in Immunity and Mucosal Homeostasis in the Gut. Mucosal Immunology, 4, 603-611.

[54]   Blanco, L.P. and Dirita, V.J. (2006) Antibodies Enhance Interaction of Vibrio cholerae with Intestinal M-Like Cells. Infection and Immunity, 74, 6957-6964.

[55]   Son, M.S. and Taylor, R.K. (2011) Vibriocidal Assays to Determine the Antibody Titer of Patient Sera Samples. Current Protocols in Microbiology, 6A.3.1-6A.3.9.

[56]   Harris, A.M., et al. (2009) Antigen-Specific Memory B-Cell Responses to Vibrio cholerae O1 Infection in Bangladesh. Infection and Immunity, 77, 3850-3856.

[57]   Bishop, A.L. and Camilli, A. (2011) Vibrio cholerae: Lessons for Mucosal Vaccine Design. Expert Review of Vaccines, 10, 79-94.

[58]   Viret, J.F., et al. (1999) Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria. Infection and Immunity, 67, 3680-3685.

[59]   Bump, J.B., Reich, M.R. and Johnson, A.M. (2013) Diarrhoeal Diseases and the Global Health Agenda: Measuring and Changing Priority. Health Policy and Planning, 28, 799-808.

[60]   Kabir, S. (2014) Critical Analysis of Compositions and Protective Efficacies of Oral Killed Cholera Vaccines. Clinical and Vaccine Immunology, 21, 1195-1205.

[61]   Lopez, A.L., Gonzales, M.L.A., Aldaba, J.G. and Nair, G.B. (2014) Killed Oral Cholera Vaccines: History, Development and Implementation Challenges. Therapeutic Advances in Vaccines, 2, 123-136.

[62]   Czerkinsky, C. and Holmgren, J. (2015) Vaccines against Enteric Infections for the Developing World. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 370, Article ID: 20150142.

[63]   Levine, M.M. (2010) Immunogenicity and Efficacy of Oral Vaccines in Developing Countries: Lessons from a Live Cholera Vaccine. BMC Biology, 8, 129.

[64]   Nascimento, I.P. and Leite, L.C. (2012) Recombinant Vaccines and the Development of New Vaccine Strategies. Brazilian Journal of Medical and Biological Research, 45, 1102-1111.

[65]   Esser, M.T., et al. (2003) Memory T Cells and Vaccines. Vaccine, 21, 419-430.

[66]   Sarkander, J., Hojyo, S. and Tokoyoda, K. (2016) Vaccination to Gain Humoral Immune Memory. Clinical & Translational Immunology, 5, e120.

[67]   Shin, S., Desai, S.N., Sah, B.K. and Clemens, J.D. (2011) Oral Vaccines against Cholera. Clinical Infectious Diseases, 52, 1343-1349.

[68]   Qadri, F., et al. (2005) Randomized, Controlled Study of the Safety and Immunogenicity of Peru-15, a Live Attenuated Oral Vaccine Candidate for Cholera, in Adult Volunteers in Bangladesh. The Journal of Infectious Diseases, 192, 573-579.

[69]   Taylor, C.E. and Greenough 3rd, W.B. (1989) Control of Diarrheal Diseases. Annual Review of Public Health, 10, 221-244.

[70]   Svennerholm, A.M. (2011) From Cholera to Enterotoxigenic Escherichia coli (ETEC) Vaccine Development. The Indian Journal of Medical Research, 133, 188-196.

[71]   Michalski, J., et al. (1993) CVD110, an Attenuated Vibrio cholerae O1 El Tor Live Oral Vaccine Strain. Infection and Immunity, 61, 4462-4468.

[72]   Baldauf, K.J., Royal, J.M., Hamorsky, K.T. and Matoba, N. (2015) Cholera Toxin B: One Subunit with Many Pharmaceutical Applications. Toxins, 7, 974-996.

[73]   Anh, D.D., et al. (2007) Safety and Immunogenicity of a Reformulated Vietnamese Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults. Vaccine, 25, 1149-1155.

[74]   Miller, H., Zhang, J., Kuolee, R., Patel, G.B. and Chen, W. (2007) Intestinal M Cells: The Fallible Sentinels? World Journal of Gastroenterology, 13, 1477-1486.

[75]   Liang, W., et al. (2003) Construction and Evaluation of a Safe, Live, Oral Vibrio cholerae Vaccine Candidate, IEM108. Infection and Immunity, 71, 5498-5504.

[76]   Boyd, E.F. and Waldor, M.K. (1999) Alternative Mechanism of Cholera Toxin Acquisition by Vibrio cholerae: Generalized Transduction of CTXPhi by Bacteriophage CP-T1. Infection and Immunity, 67, 5898-5905.

[77]   Lin, W., et al. (1999) Identification of a Vibrio cholerae RTX Toxin Gene Cluster That Is Tightly Linked to the Cholera Toxin Prophage. Proceedings of the National Academy of Sciences of the United States of America, 96, 1071-1076.

[78]   Garcia, L., et al. (2005) The Vaccine Candidate Vibrio cholerae 638 Is Protective against Cholera in Healthy volunteers. Infection and Immunity, 73, 3018-3024.

[79]   Waldor, M.K. and Mekalanos, J.J. (1994) Emergence of a New Cholera Pandemic: Molecular Analysis of Virulence Determinants in Vibrio cholerae O139 and Development of a Live Vaccine Prototype. The Journal of Infectious Diseases, 170, 278-283.

[80]   Coster, T.S., et al. (1995) Safety, Immunogenicity, and Efficacy of Live Attenuated Vibrio cholerae O139 Vaccine Prototype. The Lancet, 345, 949-952.

[81]   Hisatsune, K., Kondo, S., Isshiki, Y., Iguchi, T., Kawamata, Y. and Shimada, T. (1993) O-Antigenic Lipopolysaccharide of Vibrio cholerae O139 Bengal, a New Epidemic Strain for Recent Cholera in the Indian Subcontinent. Biochemical and Biophysical Research Communications, 196, 1309-1315.

[82]   Attridge, S.R., Qadri, F., Albert, M.J. and Manning, P.A. (2000) Susceptibility of Vibrio cholerae O139 to Antibody-Dependent, Complement-Mediated Bacteriolysis. Clinical and Diagnostic Laboratory Immunology, 7, 444-450.

[83]   Ogra, P.L., Faden, H. and Welliver, R.C. (2001) Vaccination Strategies for Mucosal Immune Responses. Clinical Microbiology Reviews, 14, 430-445.

[84]   Price, G.A., McFann, K. and Holmes, R.K. (2013) Immunization with Cholera Toxin B Subunit Induces High-Level Protection in the Suckling Mouse Model of Cholera. PLoS ONE, 8, e57269.

[85]   Pasetti, M.F., Simon, J.K., Sztein, M.B. and Levine, M.M. (2011) Immunology of Gut Mucosal Vaccines. Immunological Reviews, 239, 125-148.

[86]   Beverley, P.C. (2002) Immunology of Vaccination. British Medical Bulletin, 62, 15-28.

[87]   Bohles, N., Busch, K. and Hensel, M. (2014) Vaccines against Human Diarrheal Pathogens: Current Status and Perspectives. Human Vaccines & Immunotherapeutics, 10, 1522-1535.

[88]   Sack, R.B., et al. (2003) A 4-Year Study of the Epidemiology of Vibrio cholerae in Four Rural Areas of Bangladesh. The Journal of Infectious Diseases, 187, 96-101.

[89]   Burgers, W.A., et al. (2012) Measurements of Immune Responses for Establishing Correlates of Vaccine Protection against HIV. AIDS Research and Human Retroviruses, 28, 641-648.

[90]   Taylor, D.L., Kahawita, T.M., Cairncross, S. and Ensink, J.H.J. (2015) The Impact of Water, Sanitation and Hygiene Interventions to Control Cholera: A Systematic Review. PLoS ONE, 10, e0135676.